rEVO Biologics Release: ATryn Antithrombin (Recombinant) Prevents Venous Thromboembolic Events in Pregnant Patients With Hereditary Antithrombin Deficiency

Published: Feb 15, 2013

FRAMINGHAM, Mass.--(BUSINESS WIRE)--rEVO Biologics announced today the results of a major retrospective study analysis of its pivotal phase 3 studies which demonstrate that pregnant patients with hereditary antithrombin deficiency (HD) benefit from ATryn Antithrombin (Recombinant) therapy to prevent venous thromboembolic events (VTE). Presented as a poster at the February 2013 meeting of the Society for Maternal-Fetal Medicine (SMFM), this integrated analysis was led by Dr. Michael Paidas, professor at Yale School of Medicine and co-director of the Yale Women and Children’s Center for Blood Disorders. “This represents the largest known cohort of pregnant patients with HD treated with antithrombin for the prevention of VTE during a high-risk situation,” Dr. Paidas commented.

Back to news